+ Follow TRANSCEND Tag
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1051471
[Title] => Transcend introduces the Wi-Fi SD card
[Summary] => As wireless connectivity is now the ongoing trend for gadgets and tech accessories, it’s only fitting that even storage devices such as Wi-Fi SD cards get the upgrade they need to keep up.
[DatePublished] => 2013-08-05 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Technology
[SectionUrl] => technology
[URL] =>
)
[1] => Array
(
[ArticleID] => 83550
[Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
[Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.
The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.
[DatePublished] => 2001-06-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
TRANSCEND
Array
(
[results] => Array
(
[0] => Array
(
[ArticleID] => 1051471
[Title] => Transcend introduces the Wi-Fi SD card
[Summary] => As wireless connectivity is now the ongoing trend for gadgets and tech accessories, it’s only fitting that even storage devices such as Wi-Fi SD cards get the upgrade they need to keep up.
[DatePublished] => 2013-08-05 00:00:00
[ColumnID] => 0
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Technology
[SectionUrl] => technology
[URL] =>
)
[1] => Array
(
[ArticleID] => 83550
[Title] => Boehringer Ingelheim sets largest cardiovascular protection trial
[Summary] => MILAN, Italy — Boehringer Ingelheim has announced plans for the largest cardiovascular protection trial ever conducted on patients intolerant to angiotensin converting enzyme (ACE) inhibitors.
The study, announced at the European Society of Hypertension meeting, will examine the effects of the angiotensin III recepto antagonist (ARB) Micardis or telmisartan, on these patients. About 5,000 patients worldwide will be enrolled in the study.
[DatePublished] => 2001-06-18 00:00:00
[ColumnID] => 133272
[Focus] => 0
[AuthorID] =>
[AuthorName] =>
[SectionName] => Science and Environment
[SectionUrl] => science-and-environment
[URL] =>
)
)
)
abtest
